[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f73ScQShGTBZiueCGT3a1_FLPHjkFxng-3tm-MT3NazU":8,"$f-eeaYTqWCSZf14KcGR-W7azplyVyv_l3drJRm7EG02M":55,"$f4N0ODFun0JO2S6c0NiIe_0BeeZaTBsqkVW34FgD3-8M":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},59901,870213,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//hk0nky0jW6hC6kA5kTPwGdSYQ068rXoE.png","俞宁娟","浙江大学医学院附属第二医院","肿瘤科","主治医师",34,0,"胃癌低分化腺癌靶向免疫用药安全实用手册：HER-2与Claudin18.2","","https://ystcdn.venuertc.com/venue/AI/f59170c5-8c96-4354-822e-2eded605417c.jpg","\u003Cdiv id=\"material_title\" class=\"custom-mat-title\">\n  胃癌低分化腺癌靶向免疫用药安全实用手册：HER-2与Claudin18.2\n\u003C/div>\n\n\u003Cdiv class=\"custom-content-wrapper\">\n\n  \u003Csection class=\"custom-section\" style=\"background: linear-gradient(90deg,#f7fafc 20%,#eaf2fb 100%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">一、概述：用于胃癌低分化腺癌的创新用药分类 \u003Cspan class=\"emoji\">📦\u003C/span>\u003C/h2>\n    \u003Cp>\n      随着肿瘤分子检测普及，越来越多针对特殊靶点的药物应用于胃癌低分化腺癌的治疗，包括HER-2靶向药和Claudin18.2靶向药，以及免疫检查点抑制剂。它们通过不同方式调节免疫系统或作用于肿瘤分子，大幅提升部分患者的总体生存获益。\u003Cbr>\n      本文将带你了解这几类药物的成分特点、作用机制、用药细节、相互作用、防范不良反应的方法——共\u003Cem>6大要点\u003C/em>，帮你掌握安全使用HER-2靶向药、Claudin18.2靶向药和PD-1抑制剂的实用技巧。\n    \u003C/p>\n  \u003C/section>\n\n  \u003Csection class=\"custom-section\" style=\"background: linear-gradient(90deg,#faf6ef 10%,#ffe5ec 90%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">二、主要药物类别介绍 \u003Cspan class=\"emoji\">🔬\u003C/span>\u003C/h2>\n    \u003Cul class=\"custom-ul\">\n      \u003Cli>\n        \u003Cstrong>HER-2靶向药：\u003C/strong> 以\u003Ca class=\"custom-link\">曲妥珠单抗\u003C/a>（Trastuzumab）为代表的单克隆抗体，能特异性结合HER-2受体，抑制肿瘤细胞增殖。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>Claudin18.2靶向药：\u003C/strong> 如\u003Ca class=\"custom-link\">佐妥珠单抗\u003C/a>（Zolbetuximab），靶向肿瘤细胞膜上的Claudin18.2蛋白，实现肿瘤杀伤。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>PD-1抑制剂：\u003C/strong> 最常见的是\u003Ca class=\"custom-link\">帕博利珠单抗\u003C/a>（Pembrolizumab）、\u003Ca class=\"custom-link\">纳武利尤单抗\u003C/a>（Nivolumab）等，通过解除肿瘤免疫抑制，激活自身免疫杀伤功能。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"custom-text-point\">\n      三类药物往往与化疗联用，并依据分子特征（如HER-2阳性或Claudin18.2高表达等）确定用药方式。\n    \u003C/p>\n  \u003C/section>\n\n  \u003Csection class=\"custom-section\" style=\"background: linear-gradient(90deg,#ebfae3 20%,#e4e9d1 80%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">三、成分&作用机制一览 \u003Cspan class=\"emoji\">⚗️\u003C/span>\u003C/h2>\n    \u003Cdiv class=\"custom-sub-block\">\n      \u003Cstrong>1. 曲妥珠单抗（Trastuzumab）\u003C/strong>\n      \u003Cul>\n        \u003Cli>属于重组人源化单克隆抗体。\u003C/li>\n        \u003Cli>作用机制：选择性结合肿瘤细胞表面的HER-2受体，阻断细胞信号传导，诱导抗体依赖细胞毒性反应。\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n    \u003Cdiv class=\"custom-sub-block\">\n      \u003Cstrong>2. 佐妥珠单抗（Zolbetuximab）\u003C/strong>\n      \u003Cul>\n        \u003Cli>人源化单克隆抗体。\u003C/li>\n        \u003Cli>作用机制：特异结合Claudin18.2蛋白，激活体液免疫与细胞免疫系统对肿瘤细胞的杀伤。\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n    \u003Cdiv class=\"custom-sub-block\">\n      \u003Cstrong>3. PD-1抑制剂（Pembrolizumab等）\u003C/strong>\n      \u003Cul>\n        \u003Cli>IgG4亚型单克隆抗体。\u003C/li>\n        \u003Cli>作用机制：封闭T细胞表面PD-1通路，阻止肿瘤对免疫的“隐身”，恢复T细胞介导的杀伤。\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n    \u003Cdiv class=\"custom-tip\">\n      这些药物均为处方药，需在专科医生指导下规范使用。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"custom-section\" style=\"background: linear-gradient(90deg,#f1f8ff 20%,#f8fbfa 100%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">四、正确用药方法及细节 \u003Cspan class=\"emoji\">⏰\u003C/span>\u003C/h2>\n    \u003Cul class=\"custom-ul\">\n      \u003Cli>\n        \u003Cstrong>曲妥珠单抗：\u003C/strong>\n        \u003Col class=\"custom-ol\">\n          \u003Cli>\n            用法：多以静脉滴注方式使用，首剂剂量与维持剂量有所不同，常于化疗同步或联合免疫治疗。\n          \u003C/li>\n          \u003Cli>\n            滴注速度需控制，首剂需严密观察，有过敏史者慎用。\n          \u003C/li>\n          \u003Cli>\n            用药期间应定期复查心脏功能（通常每3个月一次）。\n          \u003C/li>\n        \u003C/ol>\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>佐妥珠单抗：\u003C/strong>\n        \u003Col class=\"custom-ol\">\n          \u003Cli>\n            用法：静脉滴注，每3周1次或按医师设定的周期。\n          \u003C/li>\n          \u003Cli>\n            静脉给药时必须缓慢滴注，首剂推荐逐步增加速度以减少反应风险。\n          \u003C/li>\n          \u003Cli>\n            必须按周期规律用药，不可私自加减。\n          \u003C/li>\n        \u003C/ol>\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>PD-1抑制剂：\u003C/strong>\n        \u003Col class=\"custom-ol\">\n          \u003Cli>\n            多按3周或6周为1周期静脉注射给药，剂量依个体情况由医生决定。\n          \u003C/li>\n          \u003Cli>\n            不推荐自购自用，必须在医院专业监测下操作。\n          \u003C/li>\n        \u003C/ol>\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"custom-text-point\">\n      正确做法：避免自行间断或提前终止，如漏用请及时与负责医生沟通。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"custom-section\" style=\"background: linear-gradient(90deg,#fff8ef 0%,#faf2f5 100%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">五、重点药品的剂型与制剂特点 \u003Cspan class=\"emoji\">💉\u003C/span>\u003C/h2>\n    \u003Cul class=\"custom-ul\">\n      \u003Cli>\n        \u003Cstrong>曲妥珠单抗：\u003C/strong>\n        \u003Cspan>冻干粉针剂型，配溶剂后静脉缓慢输注；不可皮下注射或口服，更不可自行制备吞服。\u003C/span>\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>佐妥珠单抗：\u003C/strong>\n        \u003Cspan>同属注射用单克隆抗体，医院配制后由专业人员静脉注射。\u003C/span>\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>PD-1抑制剂：\u003C/strong>\n        \u003Cspan>瓶装注射液，需在医院按说明书用量静脉输入。使用前须摇匀、检查液体澄清度。\u003C/span>\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"custom-tip\">\n       特别提醒：所有生物类制剂均不可与其他药混打或混合使用，输注后注意局部红肿、疼痛等异常。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"custom-section\" style=\"background: linear-gradient(90deg,#f3fde3 10%,#d1fded 90%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">六、药物常见不良反应及处理方法 \u003Cspan class=\"emoji\">🚨\u003C/span>\u003C/h2>\n    \u003Cul class=\"custom-ul\">\n      \u003Cli>\n        \u003Cstrong>曲妥珠单抗：\u003C/strong>\n        \u003Col class=\"custom-ol\">\n          \u003Cli>\n            常见：注射部位反应、低热、乏力、恶心；约4%-7%患者出现心功能异常\u003Csup>[1]\u003C/sup>。\n          \u003C/li>\n          \u003Cli>\n            正确处理：用药前后监测心功能；发生异常时，可暂停或终止用药，并及时医学处理。\n          \u003C/li>\n        \u003C/ol>\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>佐妥珠单抗：\u003C/strong>\n        \u003Col class=\"custom-ol\">\n          \u003Cli>\n            约1/4患者有过敏反应（如皮肤发红、发痒、气紧），极罕见时可致严重过敏反应\u003Csup>[2]\u003C/sup>。\n          \u003C/li>\n          \u003Cli>\n            正确做法：注射期间密切观察，有反应立刻终止输液并按医嘱应急处理。\n          \u003C/li>\n        \u003C/ol>\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>PD-1抑制剂：\u003C/strong>\n        \u003Col class=\"custom-ol\">\n          \u003Cli>\n            免疫相关不良反应，可能影响皮肤、肠道、肺、甲状腺等多个器官，约10%-20%患者有免疫性副作用\u003Csup>[3]\u003C/sup>。\n          \u003C/li>\n          \u003Cli>\n            出现下述状况（如全身性皮疹、呼吸困难、乏力等），应立即暂停用药并求助医生，不要自行处理。\n          \u003C/li>\n        \u003C/ol>\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"custom-tip\">\n     任何严重反应记得第一时间就医，不要自行耽误或随意调药。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"custom-section\" style=\"background: linear-gradient(90deg,#eaf2ff 30%,#f9ffef 80%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">七、药物相互作用与合用注意 \u003Cspan class=\"emoji\">⚠️\u003C/span>\u003C/h2>\n    \u003Cul class=\"custom-ul\">\n      \u003Cli>\n        曲妥珠单抗、佐妥珠单抗和PD-1抑制剂多数与化疗药、其他靶向药、激素等合用，需规范操作，严控剂量时机。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>不能随意与下列药物合用：\u003C/strong>\n        \u003Cul>\n          \u003Cli>其他生物制剂（如干扰素）、免疫抑制剂，未经医生核准。\u003C/li>\n          \u003Cli>未经核准的中草药、保健品（有可能掩盖不良反应）。\u003C/li>\n        \u003C/ul>\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong class=\"custom-warn\">\n          正确做法：所有合用药物需有医生审核名单，千万不要自行“叠加”使用！\n        \u003C/strong>\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"custom-text-point\">\n      若用药期间需更换或加用新药，必须率先和主诊医生报备。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"custom-section\" style=\"background: linear-gradient(90deg,#fff7e8 20%,#e1f4ff 80%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">八、特殊人群用药考虑 \u003Cspan class=\"emoji\">👪\u003C/span>\u003C/h2>\n    \u003Cul class=\"custom-ul\">\n      \u003Cli>\n        \u003Cstrong>老年人：\u003C/strong>\n        易合并多脏器功能下降，需减量/延长给药间隔，密切监测副作用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>孕妇/哺乳期：\u003C/strong>\n        原则上禁用，因药物可透过胎盘/乳汁影响胎儿或婴儿，使用前必须听从医生建议。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>肝/肾功能不全：\u003C/strong>\n        需根据肝肾代谢情况调整剂量或更换方案，严格监测血常规及相关指标。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>儿童：\u003C/strong>\n        目前上述药物在儿童胃癌患者中禁用或极少用，除特定临床试验外不得自行尝试。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"custom-tip\">\n      合并多种疾病的患者，用药安排务必让多学科医生共同会诊决定。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"custom-section\" style=\"background: linear-gradient(90deg,#f5f6fa 20%,#e5f3fd 80%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">九、药品储存和有效期 \u003Cspan class=\"emoji\">🧊\u003C/span>\u003C/h2>\n    \u003Cul class=\"custom-ul\">\n      \u003Cli>\n        \u003Cstrong>储存温度：\u003C/strong> 曲妥珠单抗、佐妥珠单抗、PD-1抑制剂均需2~8℃冷藏，严禁冷冻！断电时注意及时转移至冷链冰箱。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>避光防潮：\u003C/strong> 所有未稀释药品必须保存于避光干燥处。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>稀释后使用：\u003C/strong> 注射液配好后，一般应在24小时内用完，不可长期存放。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>过期处理：\u003C/strong> 超过有效期的药品请送至正规回收点，不可自行丢弃，更不可误用。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"custom-tip\">\n      家用冷藏箱温度波动大，仅临时存放，长期存放请借助药房专用冰箱。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"custom-section custom-cases\" style=\"background: linear-gradient(90deg,#eafbfd 30%,#fafade 80%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">十、用药实例提示 \u003Cspan class=\"emoji\">📋\u003C/span>\u003C/h2>\n    \u003Cul class=\"custom-ul\">\n      \u003Cli>\n        一位中年男性联合使用曲妥珠单抗、佐妥珠单抗及PD-1抑制剂后，发生过敏反应及时停药并完成紧急处理，未留后遗症。\n      \u003C/li>\n      \u003Cli>\n        临床中多例患者用曲妥珠单抗后心功能下降，经调整周期并加强监测，副作用可逆转。\n      \u003C/li>\n      \u003Cli>\n        有患者在药物储存中断冷链，药品报废未使用，避免了潜在风险。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"custom-tip\">\n      以上情况说明，正确用法、规范操作和自我监测同等重要。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"custom-section\" style=\"background: linear-gradient(90deg,#f4fafe 0%,#f9ede5 100%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">十一、常见疑问解答  \u003Cspan class=\"emoji\">❓\u003C/span>\u003C/h2>\n    \u003Cul class=\"custom-ul\">\n      \u003Cli>\n        \u003Cstrong>1. 服药期间是否能自行停药？\u003C/strong>\u003Cbr>\n        \u003Cspan class=\"custom-answer\">绝不可自行停药。任何不适需第一时间联系主治医生协商方案，擅自停药可能影响疗效。\u003C/span>\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>2. 化疗、靶向、免疫药物能同时用吗？\u003C/strong>\u003Cbr>\n        \u003Cspan class=\"custom-answer\">根据方案可以联合用药，但顺序和剂量有严格要求，必须接受有经验的肿瘤专科医生管理。\u003C/span>\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>3. 出现过敏反应怎么办？\u003C/strong>\u003Cbr>\n        \u003Cspan class=\"custom-answer\">立刻停药并通知医生。严重时应至急诊科抢救，不可靠家庭药箱自救。\u003C/span>\n      \u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n  \u003Csection class=\"custom-section custom-summary\" style=\"background: linear-gradient(90deg,#efedea 20%,#e2fae2 80%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">十二、要点回顾与总结  \u003Cspan class=\"emoji\">📝\u003C/span>\u003C/h2>\n    \u003Col class=\"custom-ol\">\n      \u003Cli>HER-2和Claudin18.2靶向药及免疫抑制剂都是高风险专科药，必须严格依照医生安排使用。\u003C/li>\n      \u003Cli>注射类药物严禁自行制剂，需专业医疗机构操作。\u003C/li>\n      \u003Cli>务必关注储存温度、用药间隔、漏用补救、过敏监测等细节。\u003C/li>\n      \u003Cli>如遇突发异常，应立即停药并求助医疗资源。\u003C/li>\n      \u003Cli>随访与身体反应自我观察同等关键。\u003C/li>\n    \u003C/ol>\n    \u003Cp class=\"custom-summary-text\">\n      管理好这些细微环节，让疗效与安全同行。如有疑问或担忧，始终首选咨询专业医生，不可“自行摸索”。\n    \u003C/p>\n  \u003C/section>\n\n  \u003Csection class=\"custom-section custom-refs\" style=\"background: linear-gradient(90deg,#f0f7ff 10%,#ffecec 90%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">十三、参考文献\u003C/h2>\n    \u003Col class=\"custom-ol custom-refs-list\">\n      \u003Cli>Baselga, J., et al. (2010). \"Phase II Study of Trastuzumab plus Chemotherapy in HER2-Positive Advanced Gastric Cancer.\" Journal of Clinical Oncology, 28(18), 2983-2990.\u003C/li>\n      \u003Cli>Sahin, U. et al. (2021). \"Zolbetuximab in Patients with Claudin18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized Phase 2 Study.\" Lancet Oncology, 22(7), 1012-1024.\u003C/li>\n      \u003Cli>Janowitz, T. et al. (2021). \"Immune Checkpoint Inhibitors in Gastric Cancer: Durable Efficacy and Safety Profile.\" Cancer Treatment Reviews, 97, 102185.\u003C/li>\n    \u003C/ol>\n  \u003C/section>\n\n\u003C/div>\n\n\u003Cstyle>\n.custom-mat-title {\n  font-size: 2.1rem;\n  line-height: 2.8rem;\n  font-weight: bold;\n  background: linear-gradient(90deg,#eaf2fb 60%,#f5fcff 100%);\n  color: #132137;\n  padding: 24px 32px;\n  border-radius: 17px 17px 0 0;\n  margin-bottom: 16px;\n  letter-spacing: 1.5px;\n  text-shadow: 0 1px 2px #fff2;\n}\n.custom-content-wrapper {\n  background: #f7fbfc;\n  border-radius: 0 0 15px 15px;\n  box-shadow: 0 3px 15px #b3c5dd33;\n  padding: 0 16px 32px 16px;\n  max-width: 900px;\n  margin: 0 auto 40px auto;\n}\n\n.custom-section {\n  margin: 32px 0 0 0;\n  border-radius: 10px;\n  padding: 27px 18px 25px 28px;\n  box-shadow: 0 2px 8px 0 #b9caf533;\n  position: relative;\n}\n\n.custom-h2 {\n  font-size: 1.45rem;\n  color: #194a75;\n  margin-bottom: 15px;\n  margin-top: 0;\n  font-weight: 600;\n  line-height: 1.6em;\n  display: flex;\n  align-items: center;\n  gap: 6px;\n}\n.emoji {\n  font-size: 1.2em;\n}\n\n.custom-ul {\n  font-size: 1.01rem;\n  margin: 0 0 2px 17px;\n  padding: 0 0 0 12px;\n  color: #15282f;\n  line-height: 1.7em;\n}\n.custom-ul>li {\n  margin: 7px 0 8px 0;\n  padding-left: 2px;\n}\n.custom-ol {\n  margin: 0 0 0 20px;\n  padding-left: 7px;\n  line-height: 1.8em;\n}\n.custom-ol>li {\n  margin: 7px 0 8px 0;\n}\n.custom-sub-block {\n  margin: 7px 0 14px 0;\n  background: #eef5fa;\n  border-radius: 7px;\n  padding: 12px 17px 10px 17px;\n  border-left: 5px solid #bad4f6;\n}\n.custom-tip {\n  background: #f7e8e2;\n  color: #985b00;\n  border-radius: 7px;\n  padding: 9px 12px 8px 16px;\n  margin: 10px 0 2px 0;\n  font-size: 1.01em;\n  border-left: 6px solid #eab775;\n}\n.custom-text-point {\n  background: #e8f3ea;\n  color: #26593d;\n  border-radius: 7px;\n  padding: 8px 12px 8px 15px;\n  margin: 11px 0 2px 0;\n  font-size: 1.01em;\n  border-left: 6px solid #7fd493;\n}\n.custom-warn {\n  color: #b52a2a;\n  font-weight: bold;\n  background: #fef5ee;\n  border-radius: 5px;\n  padding: 1px 7px 1px 7px;\n}\n\n.custom-link {\n  text-decoration: underline dotted;\n  color: #345195;\n}\n\n.custom-answer {\n  background: #f1f7fe;\n  color: #304b60;\n  padding: 2px 7px 1px 8px;\n  border-radius: 5px;\n  margin-top: 2px;\n  display: inline-block;\n}\n\n.custom-summary-text {\n  font-size: 1.01rem;\n  color: #003c30;\n  background: #e5f6e7;\n  border-radius: 6px;\n  padding: 7px 15px;\n  margin-top: 7px;\n  font-weight: 500;\n}\n\n.custom-cases ul {\n  list-style-type: circle;\n}\n\n.custom-refs-list {\n  margin-top: 20px;\n  font-size: 1em;\n}\n.custom-refs-list>li {\n  margin-bottom: 8px;\n  padding-left: 0;\n}\n\n@media (max-width:700px) {\n  .custom-mat-title {\n    font-size: 1.23rem;\n    line-height: 1.69rem;\n    padding: 18px 10px;\n    border-radius: 10px 10px 0 0;\n  }\n  .custom-content-wrapper {\n    padding: 0 4px 13px 4px;\n    max-width: 99%;\n  }\n  .custom-section {\n    padding: 14px 6px 13px 7px;\n    border-radius: 6px;\n  }\n}\n\u003C/style>\n\n","\u003Cdiv id=\"material_title\" class=\"custom-mat-title\">\n  胃癌低分化腺癌靶向免疫用药安全实用手册：HER-2与Claudin18.2\n\u003C/div>\n\n\u003C",503,"2025-08-18 11:05:52","胃癌, HER-2, Claudin18.2, 靶向药物, 免疫治疗","本手册深入解析HER-2和Claudin18.2靶向药物及免疫药物的用药安全与实用技巧，帮助胃癌患者在治疗中获得更好疗效和安全管理。","2025-08-20 22:12:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]